Caroline Germa - 01 Mar 2024 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Chief Medical Officer
Signature
/s/ Mark Manfredi, as Attorney-in-Fact for Caroline Germa
Issuer symbol
IKNA
Transactions as of
01 Mar 2024
Net transactions value
$0
Form type
4
Filing time
05 Mar 2024, 16:05:21 UTC
Previous filing
05 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Award $0 +579,100 $0.000000 579,100 01 Mar 2024 Common Stock 579,100 $1.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the shares subject to this option shall vest and become exercisable on September 1, 2024, with the remainder vesting in forty-two (42) equal monthly installments thereafter.